Matching articles for "Nubeqa"
In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)
The Medical Letter on Drugs and Therapeutics • June 19, 2023; (Issue 1679)
The androgen receptor inhibitor darolutamide
(Nubeqa – Bayer) has been approved by the FDA
for use in combination with docetaxel for treatment
of metastatic hormone-sensitive prostate cancer
(mHSPC). The...
The androgen receptor inhibitor darolutamide
(Nubeqa – Bayer) has been approved by the FDA
for use in combination with docetaxel for treatment
of metastatic hormone-sensitive prostate cancer
(mHSPC). The drug was previously approved for
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC).
Darolutamide (Nubeqa) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • December 16, 2019; (Issue 1587)
The FDA has approved darolutamide (Nubeqa –
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen...
The FDA has approved darolutamide (Nubeqa –
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen receptor inhibitor to be approved for this
indication; apalutamide (Erleada) and enzalutamide
(Xtandi), which are also approved for use in patients
with metastatic castration-resistant prostate cancer
(mCRPC), were approved earlier.